@article {AKINWANDE7239, author = {OLAGUOKE AKINWANDE and AMANDA MILLER and DAVID HAYES and RYAN O{\textquoteright}HARA and DANA TOMALTY and ROBERT C.G. MARTIN}, title = {Concomitant Capecitabine with Hepatic Delivery of Drug Eluting Beads in Metastatic Colorectal Cancer}, volume = {34}, number = {12}, pages = {7239--7245}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC). Patients and Methods: An Institutional Review Board-approved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (X-DEBIRI) or without (DEBIRI) capecitabine were compared. Results: Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6-month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217). Conclusion: There is no additional toxicity when adding capecitabine with DEBIRI. Concurrent capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent capecitabine was not statistically significant but there may be a trend towards improved survival.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/12/7239}, eprint = {https://ar.iiarjournals.org/content/34/12/7239.full.pdf}, journal = {Anticancer Research} }